Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Department of Gynecology and Obstetrics, Arash women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Ovarian Res. 2024 Aug 13;17(1):165. doi: 10.1186/s13048-024-01483-4.
To compare the ovarian reserve and the results of infertility treatment, as well as to investigate the relapse rate in the first year after the assisted reproductive technology (ART) cycle in patients with multiple sclerosis (MS) referred to Royan Institute.
This retrospective study was carried out to evaluate all women diagnosed with MS and referred to Royan Institute for assessment and treatment of possible infertility between 2011 and 2022. The control group consisted of randomly selected healthy women with tubal factor infertility who were referred for treatment during the same time period and matched in terms of age. A comparison was made between groups in terms of ovarian reserve and infertility treatment outcomes. Additionally, patients with MS who met the criteria were monitored via telephone to evaluate the symptoms, disability and relapse rate both pre- and post-ART.
Over the course of a decade, the database documented a total of 60 cases diagnosed with MS. Upon examination of the records, it was found that in 27 patients only admission was done without any hormonal assessment or infertility treatment cycle and 5 patients proceeded with the intrauterine insemination cycle. Eventually, 28 women with MS underwent the ART cycle and all of them were treated with interferon beta, glatiramer acetate, or some oral disease modifying therapies. No statistically significant difference in terms of the basal levels of luteinizing hormone, follicle-stimulating hormone and anti-Müllerian hormone was found between the MS and control groups (P > 0.05). Two groups were comparable in terms of menstrual status. The study revealed that both groups exhibited similarities in terms of the controlled ovarian stimulation protocol and duration, the dosage of gonadotropin administered, as well as the ovarian response type, clinical pregnancy rate, and live birth rate (P > 0.05). After follow up, only 2 patients (9.5%) reported relapse of symptoms within one year after ART.
The ovarian reserve and ovarian stimulation cycle and pregnancy outcomes following the ART cycle in MS patients were similar to the age-matched control group. The relapse rate of multiple sclerosis did not show a significant increase within a year following the ART cycle.
比较多发性硬化症（MS）患者的卵巢储备和不孕治疗结果，并调查辅助生殖技术（ART）周期后第一年的复发率。
本回顾性研究评估了 2011 年至 2022 年间在罗扬研究所被诊断为 MS 并接受评估和可能不孕治疗的所有女性患者。对照组由同期因输卵管因素不孕接受治疗的随机选择的健康女性组成，且年龄匹配。比较两组的卵巢储备和不孕治疗结果。此外，对符合条件的 MS 患者通过电话进行监测，以评估 ART 前后的症状、残疾和复发率。
在十年期间，数据库共记录了 60 例 MS 诊断病例。检查记录后发现，27 例患者仅入院但未进行任何激素评估或不孕治疗周期，5 例患者进行了宫内授精周期。最终，28 例 MS 患者接受了 ART 周期治疗，所有患者均接受了干扰素β、格拉替雷或一些口服疾病修正治疗。MS 组和对照组的基础黄体生成素、卵泡刺激素和抗苗勒管激素水平无统计学差异（P>0.05）。两组的月经状况相似。研究表明，两组在控制性卵巢刺激方案和持续时间、促性腺激素剂量以及卵巢反应类型、临床妊娠率和活产率方面相似（P>0.05）。随访后，仅 2 例患者（9.5%）在 ART 后一年内报告症状复发。
MS 患者的卵巢储备和 ART 周期后的卵巢刺激周期及妊娠结局与年龄匹配的对照组相似。ART 周期后一年内多发性硬化症的复发率没有显著增加。
